CORCEPT THERAPEUTICS INC

Based in Redwood City, California, Corcept Therapeutics is a biopharmaceutical company focused on developing medications targeting severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company's lead marketed product is Korlym, an oral medication approved for treating hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have exhausted or are ineligible for surgical treatment options.

The company's pipeline centers on selective cortisol modulators, a proprietary drug class. Relacorilant is in development for hypercortisolism, while miricorilant is being evaluated in Phase 1b trials for metabolic dysfunction-associated steatohepatitis. Dazucorilant and nenocorilant are also in the company's portfolio, with applications being explored in Lou Gehrig's disease and other indications.

Corcept operates with approximately 730 full-time employees and maintains a primarily U.S.-focused commercial operation for its approved products. The company was incorporated in Delaware in 1998 and is listed on the Nasdaq.